Summary:
A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 1.5 to 3.5 mg basimglurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy.
Qualified Participants Must:
• 18-75 yr old
•
need to have trigeminal neurlagia
•
no bipolar, no schizophrenia, cannot me on antipsychotitcs, or mood stabilizers
•
pain medication ok
Qualified Participants May Receive:
Will receive compensation for time and travel